0001171843-25-005403.txt : 20250814 0001171843-25-005403.hdr.sgml : 20250814 20250814070043 ACCESSION NUMBER: 0001171843-25-005403 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250814 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250814 DATE AS OF CHANGE: 20250814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Predictive Oncology Inc. CENTRAL INDEX KEY: 0001446159 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 331007393 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36790 FILM NUMBER: 251214234 BUSINESS ADDRESS: STREET 1: 91 43RD STREET STREET 2: SUITE 110 CITY: PITTSBURGH STATE: PA ZIP: 15201 BUSINESS PHONE: 412-432-1500 MAIL ADDRESS: STREET 1: 91 43RD STREET STREET 2: SUITE 110 CITY: PITTSBURGH STATE: PA ZIP: 15201 FORMER COMPANY: FORMER CONFORMED NAME: Precision Therapeutics Inc. DATE OF NAME CHANGE: 20180314 FORMER COMPANY: FORMER CONFORMED NAME: Precision Therapeutic Inc. DATE OF NAME CHANGE: 20180208 FORMER COMPANY: FORMER CONFORMED NAME: Skyline Medical Inc. DATE OF NAME CHANGE: 20130807 8-K 1 f8k_081325.htm FORM 8-K Form 8-K
False000144615900014461592025-08-142025-08-14iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 14, 2025

_______________________________

Predictive Oncology Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware001-3679033-1007393
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

91 43rd Street, Suite 110

Pittsburgh, Pennsylvania 15201

(Address of Principal Executive Offices) (Zip Code)

(412) 432-1500

(Registrant's telephone number, including area code)

 

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $0.01 par valuePOAINasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 2.02. Results of Operations and Financial Condition.

 

On August 14, 2025, Predictive Oncology Inc. issued a press release attached hereto as Exhibit 99.1 announcing its financial results for the quarter ended June 30, 2025.

 

Item 9.01. Financial Statements and Exhibits.

 

(a) Not applicable.

 

(b) Not applicable.

 

(c) Not applicable.

 

(d) Exhibits

 

Exhibit No. Description
   
99.1 Press release dated August 14, 2025
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 Predictive Oncology Inc.
   
  
Date: August 14, 2025By: /s/ Josh Blacher        
  Josh Blacher
  Interim Chief Financial Officer
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

PITTSBURGH, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended June 30, 2025, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.0 million.

Q2 2025 and Recent Highlights:

  • Continued to advance preparations for an aggressive market expansion of ChemoFx®, its validated flagship live cell drug response assay, in the U.S. and de novo Launch in Europe.
    • By testing multiple chemotherapies on a patients’ cancer cells before treatment selection, ChemoFx helps determine which chemotherapies are more likely to be effective on the tumor and which are less likely to provide benefit to the patient.
    • These data enable oncologists to make better and faster treatment decisions – eliminating the current “trial-and-error” approach – which could go a long way towards improving patient outcomes.
    • The ChemoFx treatment selection marker and tumor profiling assay will initially focus on ovarian and other gynecological cancers and may include testing of other major tumor types of interest over time.
  • Successfully developed two distinct and unique 3D liver toxicity models exclusively for Labcorp, a global leader of innovative and comprehensive laboratory services, including a human and rat model. Both models represent the liver microenvironment and can be used for the evaluation of both drug metabolism and liver toxicity related to drugs.
  • Announced that, using publicly available datasets on drugs that have either been abandoned or discontinued by large pharmaceutical companies, Predictive has developed a portfolio of promising candidates that may potentially be repurposed for additional or alternative indications.
    • Predictive Oncology’s initial screening approach on a small, curated cohort of abandoned drugs identified three compounds that warrant further exploration in new colon and breast tumor indications.
    • Specifically, Afuresertib (breast), Alisertib (colon) and Entinosta (colon) demonstrated the highest proportion of hits within those two tumor types.
    • Predictive Oncology is currently expanding this approach to evaluate additional abandoned drugs using publicly available data sets.
  • Announced a standby equity purchase agreement for up to $10 million with YA II PN, LTD, an investment fund managed by Yorkville Advisors Global, LP.

“In addition to making noteworthy advancements in validating our proprietary technologies, during the second quarter 2025 and subsequent period, we also took meaningful steps toward strengthening our financial position while also creating a foundation from which to generate meaningful revenues in 2026 and beyond,” stated Raymond Vennare, Chairman and Chief Executive Officer of Predictive Oncology. “While we remain acutely focused on our core AI-driven drug and biomarker discovery and drug repurposing initiatives, we are also working tirelessly to expand availability of our proprietary ChemoFx live-cell tumor profiling assay in the U.S. while preparing for a de novo launch in Europe, both anticipated in Q4 of this year. ChemoFx not only represents significant potential revenue for our Company, but it is also the primary assay by which we populated our vast biobank of more than 150,000 patient tumor samples, which we regard as a key differentiator.”

“Importantly, the share purchase agreement that we announced just a few weeks ago with Yorkville Advisors represents an efficient and flexible source of capital that we can utilize to advance these initiatives. We are grateful to the Yorkville team for their support of our company and our vision, and we look forward to a long and mutually beneficial partnership,” Mr. Vennare added.

Q2 2025 Financial Summary:

  • Concluded the second quarter of 2025 with $506,078 in cash and cash equivalents, compared to $611,822 as of December 31, 2024, and a stockholders’ deficit of $1,653,400 as compared to a stockholders’ deficit of $202,610 as of December 31, 2024. During the second quarter, the Company raised approximately $586,000 in combined gross proceeds through a private placement and its At-the-Market (ATM) facility.
  • Basic and diluted loss per common share from continuing operations for the quarter ended June 30, 2025, was $0.22, as compared to $0.53 for the quarter ended June 30, 2024.

Q2 2025 Financial Results:

  • The Company recorded revenue of $2,682 and $67,255 in the three months ended June 30, 2025, and 2024, respectively. The decrease in revenue from the comparative period was primarily due to decreased sales of tumor-specific 3D models and 3D kits in the three months ended June 30, 2025.
  • General and administrative expenses increased by $50,481 to $1,875,655 in the three months ended June 30, 2025, compared to $1,825,174 in the comparable period in 2024. The increase was primarily due to increased legal fees, offset by decreased fees to consultants and outside advisors, as well as decreased employee compensation related to lower headcount.
  • Operations, research and development expenses decreased by $58,977 to $499,715 in the three months ended June 30, 2025 compared to $558,692 in the comparable period in 2024. The decrease was primarily due to decreased headcount and decreased consultant fees.
  • Sales and marketing expenses increased by $134,773 to $268,959 in the three months ended June 30, 2025, compared to $134,186 in the comparable period in 2024. The increase was primarily due to increased fees for digital marketing consultants, partially offset by lower employee compensation resulting from lower headcount.
  • Net cash used in operating activities of continuing operations was $4,280,632 in the six months ended June 30, 2025, compared to $5,504,158 in the six months ended June 30, 2024. Cash used in operating activities of continuing operations decreased in the 2025 period primarily due to lower cash operating losses, partially offset by increased cash used in working capital. Lower cash operating losses were primarily due to decreased operating expenses. Cash used in working capital increased due to increases in prepaid expenses and decreases in operating lease liabilities, offset by increases in accounts payable and accrued expenses. The increases in accounts payable and accrued expenses were partially offset by the write-offs of aged accounts payable and related accrued expenses.

Forward-Looking Statements:
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, the risks related to the success of our collaboration arrangements, commercialization activities and product sales levels by our collaboration partners, and other factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:
Michael Moyer
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com

PREDICTIVE ONCOLOGY INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
 
 June 30,
2025		 December 31,
2024
ASSETS       
Current assets:       
Cash and cash equivalents$506,078  $611,822 
Accounts receivable 22,957   34,154 
Inventories 42,706   45,760 
Prepaid expense and other assets 603,930   272,779 
Current assets of discontinued operations 47,723   1,261,403 
Total current assets 1,223,394   2,225,918 
        
Property and equipment, net 284,654   347,588 
Intangibles, net 48,667   50,955 
Lease right-of-use assets 1,776,142   2,047,241 
Other long-term assets 98,478   98,478 
Non-current assets of discontinued operations 4,031   202,337 
Total assets$3,435,366  $4,972,517 
        
LIABILITIES AND STOCKHOLDERS’ DEFICIT       
Current liabilities:       
Accounts payable$1,346,499  $1,044,394 
Note payable 265,501   - 
Accrued expenses and other liabilities 1,139,294   1,236,378 
Contract liabilities 149,076   224,076 
Lease liability 602,865   555,169 
Current liabilities of discontinued operations 342,204   533,384 
Total current liabilities 3,845,439   3,593,401 
        
Lease liability – net of current portion 1,243,327   1,558,239 
Non-current liabilities of discontinued operations -   23,487 
Total liabilities 5,088,766   5,175,127 
        
        
Stockholders’ deficit:       
Preferred stock, 20,000,000 shares authorized inclusive of designated below       
Series B Convertible Preferred Stock, $.01 par value, 2,300,000 shares authorized, 79,246 shares outstanding as of June 30, 2025 and December 31, 2024 792   792 
Common stock, $.01 par value, 200,000,000 shares authorized, 9,596,737 and 6,666,993 shares outstanding as of June 30, 2025, and December 31, 2024, respectively 95,967   66,670 
Additional paid-in capital 183,189,447   180,156,199 
Accumulated deficit (184,939,606)  (180,426,271)
Total stockholders’ deficit (1,653,400)  (202,610)
        
Total liabilities and stockholders’ deficit$3,435,366  $4,972,517 
        

 


PREDICTIVE ONCOLOGY INC.
CONDENSED CONSOLIDATED STATEMENTS OF NET LOSS
(Unaudited)
 
 Three Months Ended Six Months Ended
 June 30,
 June 30,
 2025 2024 2025 2024
Revenue$2,682  $67,255  $112,992  $72,113 
Cost of sales 18,221   13,858   63,339   36,291 
Gross profit (loss) (15,539)  53,397   49,653   35,822 
                
Operating expenses:               
General and administrative 1,875,655   1,825,174   3,703,855   4,150,838 
Operations, research and development 499,715   558,692   1,020,121   1,188,777 
Sales and marketing 268,959   134,186   272,592   742,896 
Total operating expenses 2,644,329   2,518,052   4,996,568   6,082,511 
Total operating (loss) (2,659,868)  (2,464,655)  (4,946,915)  (6,046,689)
Other income 682,424   9,461   685,852   28,118 
Other expense (1,451)  (1,834)  (3,248)  (3,571)
Gain on derivative instruments -   359   -   1,368 
Loss from continuing operations (1,978,895)  (2,456,669)  (4,264,311)  (6,020,774)
Loss from discontinued operations (91,567)  (724,592)  (249,024)  (1,379,330)
Net (loss)$(2,070,462) $(3,181,261) $(4,513,335) $(7,400,104)
                
Loss per common share, basic and diluted:               
Loss from continuing operations$(0.22) $(0.53) $(0.52) $(1.38)
Loss from discontinued operations (0.01)  (0.15)  (0.03)  (0.32)
Net (loss) per common share, basic and diluted$(0.23) $(0.68) $(0.55) $(1.70)
                
Weighted average shares used in computation – basic and diluted 9,108,984   4,664,771   8,136,008   4,363,812 

 EX-101.SCH 3 gnw-20250101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20250101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20250101_lab.xml XBRL LABEL FILE Class of Stock [Axis] Class A Common Stock, $.01 par value Class B Common Stock, $.01 par value Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20250101_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.25.2
Cover
Aug. 14, 2025
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 14, 2025
Entity File Number 001-36790
Entity Registrant Name Predictive Oncology Inc.
Entity Central Index Key 0001446159
Entity Tax Identification Number 33-1007393
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 91 43rd Street, Suite 110
Entity Address, City or Town Pittsburgh
Entity Address, State or Province PA
Entity Address, Postal Zip Code 15201
City Area Code 412
Local Phone Number 432-1500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.01 par value
Trading Symbol POAI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_081325.htm gnw-20250101.xsd gnw-20250101_def.xml gnw-20250101_lab.xml gnw-20250101_pre.xml http://xbrl.sec.gov/dei/2025 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "f8k_081325.htm": { "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20250101", "dts": { "inline": { "local": [ "f8k_081325.htm" ] }, "schema": { "local": [ "gnw-20250101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "definitionLink": { "local": [ "gnw-20250101_def.xml" ] }, "labelLink": { "local": [ "gnw-20250101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20250101_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2025": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2025": 22 }, "report": { "R1": { "role": "http://globenewswire.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_081325.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_081325.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentDescription", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AnnualInformationForm", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "gnw_ClassBCommonStock.01ParValueMember": { "xbrltype": "domainItemType", "nsuri": "http://globenewswire.com/20250101", "localname": "ClassBCommonStock.01ParValueMember", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class B Common Stock, $.01 par value" } } }, "auth_ref": [] }, "gnw_ClassCommonStock.01ParValueMember": { "xbrltype": "domainItemType", "nsuri": "http://globenewswire.com/20250101", "localname": "ClassCommonStock.01ParValueMember", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class A Common Stock, $.01 par value" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfStockDomain", "presentation": [ "http://globenewswire.com/role/Cover" ], "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CountryRegion", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodStartDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentQuarterlyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine3", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPrimarySicNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitySmallBusiness", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Extension", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoTradingSymbolFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12gTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityReportingObligation", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementClassOfStockAxis", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementLineItems", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementTable", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001171843-25-005403-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-25-005403-xbrl.zip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f8k_081325_htm.xml IDEA: XBRL DOCUMENT 0001446159 2025-08-14 2025-08-14 iso4217:USD shares iso4217:USD shares false 0001446159 8-K 2025-08-14 Predictive Oncology Inc. DE 001-36790 33-1007393 91 43rd Street, Suite 110 Pittsburgh PA 15201 412 432-1500 false false false false Common stock, $0.01 par value POAI NASDAQ false